J. Chauvergne

发表

Familial cluster of ovarian small cell carcinoma: a new mendelian entity?

M. Longy, M. Trojani, C. Toulouse, 1996, Journal of medical genetics.

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1996, European journal of cancer.

High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).

F. Mayer, F. Joly, J. Macé-Lesec’h, 2000, Gynecologic oncology.

Hodgkin's disease in the elderly: A series of 30 patients aged older than 70 years

I. de Mascarel, M. Durand, B. Hoerni, 1984, Cancer.

BCG in the immunotherapy of malignant lymphomas

M. Durand, C. Lagarde, J. Chauvergne, 1977, Cancer Immunology, Immunotherapy.

Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens.

J. Berlie, M. Carton, E. Pommatau, 1978, European journal of cancer.

[Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients].

P. Fargeot, C. Lhommé, A. Goupil, 1993, Bulletin du cancer.

Evaluation of whole abdominal irradiation in ovarian carcinoma with a four orthogonal fields technique.

E. Bussières, L. Thomas, C. Toulouse, 1994, International journal of radiation oncology, biology, physics.

Phase II study of cystemustine in advanced head and neck cancer. A trial of the EORTC Clinical Screening Group.

P. Chollet, M. Degardin, J. Chauvergne, 1995, European journal of cancer. Part B, Oral oncology.

Original article: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen

L. Mauriac, M. Durand, F. Bonichon, 1992 .

[Chemotherapy of Hodgkin's disease].

B. Hoerni, J. Chauvergne, G. Simon, 1970, Bordeaux medical.

Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.

M. Namer, P. Kerbrat, R. Bugat, 1989, Seminars in oncology.

Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial.

Y. Bécouarn, B. Nguyen, R. Brunet, 1986, European journal of cancer & clinical oncology.

Successful Maintenance Immunotherapy by BCG of Non‐Hodgkin's Malignant Lymphomas: Results of a Controlled Trial *

M. Durand, P. Richaud, A. Mascarel, 1979, British journal of haematology.

Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I-IIIA.

I. de Mascarel, B. Hoerni, F. Bonichon, 1988, European journal of cancer & clinical oncology.

Non-Hodgkin malignant lymphomas. Clinico-pathologic correlations with the Kiel classification. Retrospective analysis of a series of 274 cases.

M. Durand, B. Hoerni, P. Richaud, 1978, European journal of cancer.

Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination

J. Coindre, M. Durand, R. Brunet, 2004, Cancer Chemotherapy and Pharmacology.

Malignant Lymphoplasmacytoid Lymphomas. Clinical and Evolutive Data

M. Durand, B. Hoerni, H. Eghbali, 1978, Tumori.

[Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].

J. Armand, M. Durand, J. Chauvergne, 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.

B. Bui, L. Mauriac, M. Durand, 1984, Cancer treatment reports.

Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin

T. Conroy, G. Prévot, M. Spielmann, 1994, American journal of clinical oncology.

Cis-platinum-diammino-dichloro (CPDD) in chemotherapy of cancers: Phase II therapeutic trial

G. Mathé, F. Muggia, M. Bayssas, 1978 .

[Fever in Hodgkin's disease. Pathogenic hypothesis].

B. Hoerni, M. Parsi, J. Chauvergne, 1970, La Presse medicale.

Hodgkin's disease, clinical stages I and II. Results of radical irradiation with or without chemotherapy.

B. Hoerni, P. Richaud, H. Eghbali, 1980, Acta radiologica. Oncology.

[Palliative chemotherapy of adult soft tissue sarcomas with an association of cyclophosphamide-vincristine-adriamycine-dacarbazine (CYVADIC) (author's transl)].

B. Bui, M. Durand, R. Brunet, 1981, Bulletin du cancer.

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.

A. Ravaud, J. Coindre, G. Kantor, 1992, British Journal of Cancer.

[Chemotherapy of disseminated malignant melanoma].

J. Chauvergne, B. Clavel, T. Klein, 1978, La Nouvelle presse medicale.

[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].

P. Fargeot, J. Berlie, M. George, 1990, Bulletin du cancer.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[Cancers of the breast at metastatic high-risk: prediction of survival by steroidal receptors].

L. Mauriac, M. Durand, J. Wafflart, 1989, Bulletin du Cancer.

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre

M. Dilhuydy, L. Mauriac, M. Durand, 1988, Breast Cancer Research and Treatment.

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

J. Armand, P. Fumoleau, P. Kerbrat, 1993, European journal of cancer.

Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.

M. van Glabbeke, P. Hérait, J. Armand, 1992, European journal of cancer.

[Significance of chemotherapy complementary to radiotherapy in stages I and II in Hodgkin's disease].

M. Durand, B. Hoerni, C. Lagarde, 1975, Bulletin du Cancer.

Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].

L. Mauriac, M. Durand, F. Bonichon, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.

B. Hoerni, H. Eghbali, G. Hoerni-simon, 1978, Acta radiologica: oncology, radiation, physics, biology.

Induction chemotherapy of non-Hodgkin's malignant lymphomas. Preliminary results of a controlled trial.

M. Durand, B. Hoerni, C. Lagarde, 1977, European journal of cancer.

Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.

J. Robert, S. Huet, J. Chauvergne, 1988, European journal of cancer & clinical oncology.

[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].

G. Mathé, F. Muggia, M. Bayssas, 1979, La Nouvelle presse medicale.

[Combination treatment of localised breast cancers with a high risk of metastatic disease. The results of a prospective controlled study (author's transl)].

M. Durand, B. Hoerni, P. Richaud, 1981, Journal de gynecologie, obstetrique et biologie de la reproduction.

[IgD myeloma].

B. Hoerni, C. Meugé, J. Chauvergne, 1970, La Presse medicale.

[A case of choroid metastasis of choriocarcinoma].

C. Meugé, J. Chauvergne, J. Le Rebeller, 1975, Bulletin des societes d'ophtalmologie de France.

[Randomized trial of initial chemotherapy with cisplatin alone or in combination in 241 advanced carcinomas of the upper respiratory and digestive tract].

P. Fargeot, L. Meeus, L. Traissac, 1988, Annales d'Oto-Laryngologie et de Chirurgie Cervico-Faciale.

[A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck. Analysis of a series of 209 patients].

P. Fargeot, L. Meeus, J. Chauvergne, 1988, Bulletin du Cancer.

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.

M. van Glabbeke, P. Fumoleau, V. Diéras, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of a randomized trial comparing short vs prolonged chemotherapy in metastatic breast cancer

L. Mauriac, M. Durand, C. Toulouse, 1993 .

[Imipramine used as major analgesic in carcinology. Study of 118 cases].

C. Lagarde, J. Chauvergne, A. Hugues, 1963, La Presse medicale.

BCG in the immunotherapy of Hodgkin's disease and non-Hodgkin's lymphomas

M. Durand, C. Lagarde, R. Brunet, 1976, Cancer Immunology, Immunotherapy.

[Chemotherapy of reticulosarcomas and lymphosarcomas. A 10-year analysis].

M. Durand, C. Meugé, G. Hoerni-simon, 1974, Bulletin du Cancer.

[Hodgkin's-like animal reticulopathies. Their significance for the study of human disease].

B. Hoerni, E. Legrand, J. Chauvergne, 1970, Bulletin du Cancer.

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

I. de Mascarel, B. Hoerni, F. Bonichon, 1989, British Journal of Cancer.

[Chemotherapy of Hodgkin's disease].

B. Hoerni, J. Chauvergne, G. Simon, 1970, Bordeaux medical.

Phase II study of cystemustine in advanced eenal cancer

J. Madelmont, V. Diéras, P. Fargeot, 1995 .

[Conservative loco-regional treatment of soft tissue sarcoma in adults after induction chemotherapy].

J. Coindre, P. Richaud, A. Avril, 1985, Presse medicale.

[Non-Hodgkin's malignant lymphomas. Clinico-pathological data and course in 370 patients (author's transl)].

M. Durand, B. Hoerni, P. Richaud, 1980, Bulletin du cancer.

[Functional outcome of laparoscopically transposed ovaries in the multidisciplinary treatment of cervical cancers. Analysis of risk factors].

A. Avril, L. Thomas, F. Lakdja, 1996, Journal de gynecologie, obstetrique et biologie de la reproduction.